Ruijin Hospital

Huawei Launches the Medical Technology Digitalization Solution to Accelerate Intelligence in Healthcare

Retrieved on: 
Wednesday, February 28, 2024
ICT, Marketing, Hospital, Pathology, Internet of things, Data collection, Ruijin Hospital, Health Bureau (Macau), CPU cache, Diagnosis, Wi-Fi, Digital

BARCELONA, Spain, Feb. 28, 2024 /PRNewswire/ -- During MWC Barcelona 2024, Huawei officially launched its Medical Technology Digitalization Solution as part of its effort to lead the digital and intelligent upgrade of the healthcare industry.

Key Points: 
  • BARCELONA, Spain, Feb. 28, 2024 /PRNewswire/ -- During MWC Barcelona 2024, Huawei officially launched its Medical Technology Digitalization Solution as part of its effort to lead the digital and intelligent upgrade of the healthcare industry.
  • David Shi, Vice President of Huawei's ICT Marketing & Solution Sales, said, "To accelerate the intelligent upgrade of the healthcare industry, Huawei, as an ICT provider, builds a secure and sustainable digital foundation for the healthcare industry and helps it go intelligent."
  • Thousands of images read in seconds, accelerating the digital & intelligent upgrade of medical technology services
    The medical technology digitalization solution focuses on pathology and medical imaging.
  • So far, Huawei has served over 5000 hospitals and medical institutions in more than 110 countries and regions.

AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Principal, Ruijin Hospital, Fabry disease, Enzyme replacement therapy, GCS, Pharmacokinetics, Strong, Nephrology, Safety, Therapy, Patient, Pharmaceutical industry

AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.

Key Points: 
  • AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
  • AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed to treat glycosphingolipid storage diseases, including Fabry Disease and Type 1 Gaucher Disease.
  • “We are delighted to initiate enrollment in our Phase 2 study for patients with Fabry disease at one of the most renowned academic centers in China,” said Dr. Pedro Huertas, M.D.
  • I am excited to have dosed the first patient in the company’s Phase 2 program for AL01211 and am dedicated to maintaining the highest standards throughout the trial.”

AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, PK, PD, IV, Aes, Clinical trial, Fabry disease, Pharmacokinetics, Quality of life, Ruijin Hospital, Nephrology, Trust, Patient, CDE, National Medical Products Administration, GCS, Principal, Center for Drug Evaluation and Research, Therapy, Strong, IND, NMPA, Safety, Pharmaceutical industry, Fabry

AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.

Key Points: 
  • AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
  • AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease.
  • It has completed a phase 1 clinical trial in healthy volunteers in Australia and a bridging phase 1 trial in China under IND approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
  • With this in mind, we are truly excited about our participation in this trial, as we strive to improve the daily lives of patients with Fabry disease.”

Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic

Retrieved on: 
Tuesday, January 31, 2023
The Spring Festival, United Front Work Department, Indian Express Limited, Fever, Fudan University, Q&A, Tibet Autonomous Region, Hospital, Power Construction Corporation of China, Infection, Central Committee of the Chinese Communist Party, Commercial bank, Health, Medicine, Volunteering, New Year, The Good Doctor, Weather, Atmosphere, Assistant, The Bund Finance Center, Collaborative Project to Increase Production of Rural Doctor, Mahidol University, Tablet, SF Express, Chinese New Year, Ruijin Hospital, Consultant, CO-oximeter, Huashan Hospital, Spring Festival, City of Hope National Medical Center, Fosun Pharma, Industrial and Commercial Bank of China, COVID-19, China Institute for Innovation and Development Strategy, Negotiation, Industrial, Cough, City, Pharmaceutical industry, Fosun International, Azvudine

First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival?

Key Points: 
  • First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival?
  • While negotiating cooperation with SF Express, Fosun Foundation urgently recruited nearly a hundred employee volunteers within Fosun and its subsidiaries.
  • Coordinating with their plan of returning home during the Spring Festival, the volunteers personally delivered medication to the donated counties.
  • We hope play its due role in the revitalization of Chinese rural areas and the construction of a healthy China."

A Healthy Winter Action: Second Batch of 19,600 Bottles of Azvudine Delivered to 24 Counties

Retrieved on: 
Friday, January 20, 2023
Cloud, Central Committee of the Chinese Communist Party, The Spring Festival, The Bund Finance Center, United Front Work Department, N95, Health Bureau (Macau), Collaborative Project to Increase Production of Rural Doctor, Mahidol University, Maternal and Child Health Bureau, Zhejiang University, Child, Diagnosis, Q&A, Spring Festival, Volunteering, RMB, Fosun Pharma, The Good Doctor, Treatment, COVID-19, Oxygen mask, Ruijin Hospital, Haikou Meilan International Airport, LTD, Prognosis, ICBC, City, Chengdu Shuangliu International Airport, Tea, Bottled water, Pharmaceutical industry, Fosun International, Yangtze, Puge County, Azvudine, Lingao County

HONG KONG, Jan. 20, 2023 /PRNewswire/ -- On January 16, the second stage of "A Healthy Winter Action" initiated by Fosun Foundation in conjunction with other institutions kicked off, with 19,600 bottles of Azvudine gradually shipped to the rural clinics of 24 counties across Sichuan, Chongqing, Gansu, Hainan, Yunnan, Guizhou and Jiangxi provinces. The drugs were donated together with the epidemic prevention packages from many benevolent enterprises and institutions, among which, some medical supplies, such as oxygenators, oximeters, antigen test kits, and N95 masks were much needed in the rural areas.

Key Points: 
  • Immediately after the around-the-clock delivery of the first batch of 6,000 bottles of Azvudine in the A Healthy Winter Action, the volunteers from Fosun and the resident teams for Rural Doctors Program in the rural areas started out for the second-stage delivery.
  • 19,600 bottles of Azvudine in 98 cartons were successively shipped out from Shanghai on January 16 and expected to help at least 20,000 villagers, most of whom were seniors over 65, to stay safer amid the epidemic.
  • 33 Business Management Co., LTD, Wuxi Yushou Medical Appliances Co., Ltd., Shanghai Tuyue Business Advisory Co., Ltd., Shede Spirits, Jinhui Liquor, Hainan Mining, Golte.
  • The medicines will be donated to 100 counties in rural areas in stages during the Spring Festival, and all donations will be completed after the Spring Festival.

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

Retrieved on: 
Thursday, December 29, 2022
Fudan University, Clinical trial, HKEX, The New England Journal of Medicine, AE, Article, Renji Hospital, RNA polymerase II, Ruijin Hospital, Smoking, SSE, Overweight, III, NEJM, COVID-19, Transport, Death, Female, FAS, Trial of the century, Shanghai Jiao Tong University School of Medicine, AES, BMI, Patient, Cardiovascular disease, Severe acute respiratory syndrome coronavirus 2, Development, Omicron, Safety, Hypertension, Hospital, Obesity, Șaeș, Diabetes, Incidence, HR, Pharmaceutical industry, Medicine

It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

Key Points: 
  • It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.
  • The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.
  • Finally, a total of 771 patients (Full Analysis Set, FAS) were treated with VV116 (n = 384) or PAXLOVID (n = 387).
  • The incidence of AEs in VV116 group was lower than that in the PAXLOVID group (all-grade AEs: 67.4% vs. 77.3%, Grade 3 or 4 AE: 2.6% vs. 5.7%).

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

Retrieved on: 
Wednesday, November 16, 2022
Monroe Dunaway Anderson, Anderson, Fudan University, Forward-looking statement, Meeting, University, Company, Nursing management, Education, NYSE, CCM, Research, Phrase, The Meeting, Patient, Radiation, Renji Hospital, Hospital, Shanghai Cancer Center, Oncology, MD Anderson Cancer Center, Method, Ruijin Hospital, Cancer, Pharmaceutical industry, Medical device, Medical imaging, Immunotherapy, Bedside

12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.

Key Points: 
  • 12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.
  • Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I would like to express my heartfelt thanks to the experts who spoke on and participated in the Meeting.
  • MD Anderson is one of the best-known cancer treatment centers globally and the largest cancer center in the United States.
  • Leveraging years of strategic cooperation, MD Anderson and Shanghai Concord Cancer Center successfully cohosted the First Annual Academic Meeting in November 2021.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022
Efficacy, Control, NDA, Safety, Ophthalmology, Cancer, Eli Lilly and Company, Medicine, KRAS, News, Nature, Integrity, Marketing, American Society of Clinical Oncology, NSCLC, CMC, SAN, Housing and Building National Research Center, Social conditions in Honduras, Motherboard, Company, Autoimmunity, Sintilimab, Patient, Ruijin Hospital, FGFR2, Shanghai Jiao Tong University School of Medicine, ASCO, Eli Lilly, HKEX, MD Anderson Cancer Center, Translational medicine, TKI, TIK, Environment, PI3K, Bevacizumab, Society, Chemistry, BCL, Stock exchange, NMPA, State Key Laboratories, Pharmaceutical industry, Medical device, Generic drug, Spotlight Innovation, Incyte, Ramucirumab, Hematology

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

Retrieved on: 
Friday, September 17, 2021
People, WebRTC, Degenerative disease, Wu Zhongchao, Efficiency, Technology, Hematology, Forward-looking statement, MDT, Coronavirus, First Affiliated Hospital of Xinjiang Medical University, Patient, Company, Private Securities Litigation Reform Act, Microbiology, Second Affiliated Hospital of Xinjiang Medical University, Disease, Human, Physician, Infection, Medicine in China, Hospital, NASDAQ, Solution, Growth, Chinese Medical Doctor Association, Neoplasm, Review, Learning, Lists of diseases, Guangzhou Medical University, Diagnosis, Goal, SEC, Cancer, 301 Hospital, Chongqing Medical University, Ruijin Hospital, Medicine, Public relations

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").

Key Points: 
  • SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").
  • The Hematology MDT Platform provides clinicians with a channel to learn multidisciplinary thinking skills online, in order to improve diagnosis and treatment and further the efficiency of treatment.
  • In addition, physicians can watch MDT training videos to learn the clinical thinking skills from experts and improve their problem-solving ability during the disease diagnosis and treatment.
  • Zhongchao's Hematology MDT platform provides physicians with a convenient and rapid access to learn and exchange MDT practices and experiences andwill promote the development of hematology treatment models in China.

Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

Retrieved on: 
Monday, August 30, 2021
Company, Disaster, U.S. Securities and Exchange Commission, Adoption, GLOBE, Arrhythmia, Physician, Pandemic, Ruijin Hospital, Marketing, Forward-looking statement, NYSE, Hospital, Health, Electrophysiology, Safety, Partnership, Patient, Robotics, CEO, 3D, Genesis, Robotic magnetic navigation, MicroPort, Technology, Security (finance), Medical imaging, Medical device

ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. ( MicroPort EP ) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.

Key Points: 
  • ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. ( MicroPort EP ) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.
  • The agreement brings together MicroPort EPs commercial and product leadership in Chinas electrophysiology market with Stereotaxis advanced Robotic Magnetic Navigation technology.
  • As part of the collaboration, MicroPort EP will become the exclusive distributor of Robotic Magnetic Navigation technology for electrophysiology in China.
  • MicroPort EP will also pursue regulatory approvals for Stereotaxis latest innovations including the Genesis RMN system and proprietary magnetic ablation catheter.